227 related articles for article (PubMed ID: 33010230)
1. Hematopoietic Tumors in a Mouse Model of X-linked Chronic Granulomatous Disease after Lentiviral Vector-Mediated Gene Therapy.
Jofra Hernández R; Calabria A; Sanvito F; De Mattia F; Farinelli G; Scala S; Visigalli I; Carriglio N; De Simone M; Vezzoli M; Cecere F; Migliavacca M; Basso-Ricci L; Omrani M; Benedicenti F; Norata R; Rancoita PMV; Di Serio C; Albertini P; Cristofori P; Naldini L; Gentner B; Montini E; Aiuti A; Mortellaro A
Mol Ther; 2021 Jan; 29(1):86-102. PubMed ID: 33010230
[TBL] [Abstract][Full Text] [Related]
2. Non-Clinical Efficacy and Safety Studies on G1XCGD, a Lentiviral Vector for Ex Vivo Gene Therapy of X-Linked Chronic Granulomatous Disease.
Brendel C; Rothe M; Santilli G; Charrier S; Stein S; Kunkel H; Abriss D; Müller-Kuller U; Gaspar B; Modlich U; Galy A; Schambach A; Thrasher AJ; Grez M
Hum Gene Ther Clin Dev; 2018 Jun; 29(2):69-79. PubMed ID: 29664709
[TBL] [Abstract][Full Text] [Related]
3. Dual-regulated lentiviral vector for gene therapy of X-linked chronic granulomatosis.
Chiriaco M; Farinelli G; Capo V; Zonari E; Scaramuzza S; Di Matteo G; Sergi LS; Migliavacca M; Hernandez RJ; Bombelli F; Giorda E; Kajaste-Rudnitski A; Trono D; Grez M; Rossi P; Finocchi A; Naldini L; Gentner B; Aiuti A
Mol Ther; 2014 Aug; 22(8):1472-1483. PubMed ID: 24869932
[TBL] [Abstract][Full Text] [Related]
4. Lentiviral Vector Gene Therapy Protects XCGD Mice From Acute Staphylococcus aureus Pneumonia and Inflammatory Response.
Farinelli G; Jofra Hernandez R; Rossi A; Ranucci S; Sanvito F; Migliavacca M; Brombin C; Pramov A; Di Serio C; Bovolenta C; Gentner B; Bragonzi A; Aiuti A
Mol Ther; 2016 Oct; 24(10):1873-1880. PubMed ID: 27456061
[TBL] [Abstract][Full Text] [Related]
5. Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells.
Santilli G; Almarza E; Brendel C; Choi U; Beilin C; Blundell MP; Haria S; Parsley KL; Kinnon C; Malech HL; Bueren JA; Grez M; Thrasher AJ
Mol Ther; 2011 Jan; 19(1):122-32. PubMed ID: 20978475
[TBL] [Abstract][Full Text] [Related]
6. Human miR223 promoter as a novel myelo-specific promoter for chronic granulomatous disease gene therapy.
Brendel C; Hänseler W; Wohlgensinger V; Bianchi M; Tokmak S; Chen-Wichmann L; Kuzmenko E; Cesarovic N; Nicholls F; Reichenbach J; Seger R; Grez M; Siler U
Hum Gene Ther Methods; 2013 Jun; 24(3):151-9. PubMed ID: 23489116
[TBL] [Abstract][Full Text] [Related]
7. Long-term correction of phagocyte NADPH oxidase activity by retroviral-mediated gene transfer in murine X-linked chronic granulomatous disease.
Dinauer MC; Li LL; Björgvinsdóttir H; Ding C; Pech N
Blood; 1999 Aug; 94(3):914-22. PubMed ID: 10419882
[TBL] [Abstract][Full Text] [Related]
8. Third-generation, self-inactivating gp91(phox) lentivector corrects the oxidase defect in NOD/SCID mouse-repopulating peripheral blood-mobilized CD34+ cells from patients with X-linked chronic granulomatous disease.
Roesler J; Brenner S; Bukovsky AA; Whiting-Theobald N; Dull T; Kelly M; Civin CI; Malech HL
Blood; 2002 Dec; 100(13):4381-90. PubMed ID: 12393624
[TBL] [Abstract][Full Text] [Related]
9. Simian immunodeficiency virus lentivector corrects human X-linked chronic granulomatous disease in the NOD/SCID mouse xenograft.
Naumann N; De Ravin SS; Choi U; Moayeri M; Whiting-Theobald N; Linton GF; Ikeda Y; Malech HL
Gene Ther; 2007 Nov; 14(21):1513-24. PubMed ID: 17728796
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Optimization and Safety Studies of a New Lentiviral Gene Therapy for p47
Schejtman A; Vetharoy W; Choi U; Rivat C; Theobald N; Piras G; Leon-Rico D; Buckland K; Armenteros-Monterroso E; Benedetti S; Ashworth MT; Rothe M; Schambach A; Gaspar HB; Kang EM; Malech HL; Thrasher AJ; Santilli G
Hum Gene Ther; 2021 Sep; 32(17-18):949-958. PubMed ID: 33740872
[TBL] [Abstract][Full Text] [Related]
11. Chronic granulomatous disease: Clinical, molecular, and therapeutic aspects.
Chiriaco M; Salfa I; Di Matteo G; Rossi P; Finocchi A
Pediatr Allergy Immunol; 2016 May; 27(3):242-53. PubMed ID: 26680691
[TBL] [Abstract][Full Text] [Related]
12. Alpharetroviral vector-mediated gene therapy for X-CGD: functional correction and lack of aberrant splicing.
Kaufmann KB; Brendel C; Suerth JD; Mueller-Kuller U; Chen-Wichmann L; Schwäble J; Pahujani S; Kunkel H; Schambach A; Baum C; Grez M
Mol Ther; 2013 Mar; 21(3):648-61. PubMed ID: 23207695
[TBL] [Abstract][Full Text] [Related]
13. Lineage- and stage-restricted lentiviral vectors for the gene therapy of chronic granulomatous disease.
Barde I; Laurenti E; Verp S; Wiznerowicz M; Offner S; Viornery A; Galy A; Trumpp A; Trono D
Gene Ther; 2011 Nov; 18(11):1087-97. PubMed ID: 21544095
[TBL] [Abstract][Full Text] [Related]
14. Lentiviral gene therapy for X-linked chronic granulomatous disease recapitulates endogenous CYBB regulation and expression.
Wong RL; Sackey S; Brown D; Senadheera S; Masiuk K; Quintos JP; Colindres N; Riggan L; Morgan RA; Malech HL; Hollis RP; Kohn DB
Blood; 2023 Mar; 141(9):1007-1022. PubMed ID: 36332160
[TBL] [Abstract][Full Text] [Related]
15. Lentiviral gene therapy for X-linked chronic granulomatous disease.
Kohn DB; Booth C; Kang EM; Pai SY; Shaw KL; Santilli G; Armant M; Buckland KF; Choi U; De Ravin SS; Dorsey MJ; Kuo CY; Leon-Rico D; Rivat C; Izotova N; Gilmour K; Snell K; Dip JX; Darwish J; Morris EC; Terrazas D; Wang LD; Bauser CA; Paprotka T; Kuhns DB; Gregg J; Raymond HE; Everett JK; Honnet G; Biasco L; Newburger PE; Bushman FD; Grez M; Gaspar HB; Williams DA; Malech HL; Galy A; Thrasher AJ;
Nat Med; 2020 Feb; 26(2):200-206. PubMed ID: 31988463
[TBL] [Abstract][Full Text] [Related]
16. Lentiviral Gene Therapy of Chronic Granulomatous Disease: Functional Assessment of Universal and Tissue-Specific Promoters.
Yuan H; Wu X; Liu H; Chang LJ
Hum Gene Ther; 2023 Jan; 34(1-2):19-29. PubMed ID: 36274229
[TBL] [Abstract][Full Text] [Related]
17. Lentiviral gene therapy rescues p47
Schejtman A; Aragão-Filho WC; Clare S; Zinicola M; Weisser M; Burns SO; Booth C; Gaspar HB; Thomas DC; Condino-Neto A; Thrasher AJ; Santilli G
Gene Ther; 2020 Sep; 27(9):459-469. PubMed ID: 32533104
[TBL] [Abstract][Full Text] [Related]
18. Chronic Granulomatous Disease: a Comprehensive Review.
Yu HH; Yang YH; Chiang BL
Clin Rev Allergy Immunol; 2021 Oct; 61(2):101-113. PubMed ID: 32524254
[TBL] [Abstract][Full Text] [Related]
19. A Mouse Model of X-Linked Chronic Granulomatous Disease for the Development of CRISPR/Cas9 Gene Therapy.
Sevim-Wunderlich S; Dang T; Rossius J; Schnütgen F; Kühn R
Genes (Basel); 2024 May; 15(6):. PubMed ID: 38927642
[TBL] [Abstract][Full Text] [Related]
20. From bench to bedside: preclinical evaluation of a self-inactivating gammaretroviral vector for the gene therapy of X-linked chronic granulomatous disease.
Stein S; Scholz S; Schwäble J; Sadat MA; Modlich U; Schultze-Strasser S; Diaz M; Chen-Wichmann L; Müller-Kuller U; Brendel C; Fronza R; Kaufmann KB; Naundorf S; Pech NK; Travers JB; Matute JD; Presson RG; Sandusky GE; Kunkel H; Rudolf E; Dillmann A; von Kalle C; Kühlcke K; Baum C; Schambach A; Dinauer MC; Schmidt M; Grez M
Hum Gene Ther Clin Dev; 2013 Jun; 24(2):86-98. PubMed ID: 23845071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
